Today KG Legal is taking part in a business meeting with a delegation from the Free State of Thuringia, led by Minister-President Mario Voigt, hosted at the National Synchrotron Radiation Centre SOLARIS in Kraków. The meeting is organised by the Polish-German Chamber of Industry and Commerce (AHK Polska) together with the Marshal’s Office of the Małopolska Region and the Business in Małopolska centre, with LEG Thüringen, the Thuringian economic development agency, as a partner.
Synthetic data, meaning text, images and tabular records produced by algorithms rather than collected from the real world, has moved from the research lab into everyday business use. It promises datasets that can be shared, tested and used to train AI without exposing real individuals. The law, however, does not accept that promise at face value. In 2026 the European Data Protection Board stated that synthetic data is not anonymous by default, the AI Act’s transparency duties for synthetic content began to apply, and Poland established its own AI supervisory authority. This article explains how synthetic data is generated and what legal conditions its generation and use must meet.
After three years of negotiations, the reform of EU pharmaceutical legislation is one step away from completion. A new regulation and a new directive will replace the current Community code and the EMA Regulation, reshaping data and market protection periods, the rules for orphan medicines, the Bolar exemption and supply obligations. Originator and generic companies alike will need to revisit their strategies, and Poland faces a thorough overhaul of its Pharmaceutical Law.
Poland’s Ministry of Health wants to place medicines with different active substances in a single reimbursement limit group where they work in a similar way, and to reward hospitals for choosing the cheapest therapy available. The change is meant to bring prices down and free up funds for innovative treatment, but clinicians warn that cost equivalence is not the same as clinical equivalence. We examine how the proposed baskets of equivalent therapeutic technologies could affect physicians’ autonomy, patients’ rights and competition in the pharmaceutical market, and what safeguards the legislation should contain. KG LEGAL KIELTYKA GLADKOWSKI supports international pharmaceutical, biotechnology and healthcare businesses operating in Poland. For legal assistance with pharmaceutical regulation, reimbursement and market access, contact our team at office@kg-legal.pl.
The longevity economy is commonly estimated at several hundred billion dollars worldwide and continues to grow rapidly.[1] Venture capital flows into biotechnology companies that promise to slow, halt, or reverse aging. Clinics from Zurich to Seoul to Miami sell “longevity programmes.” Supplement brands attach the word “longevity” to products ranging from NAD precursors to collagen powders. And yet the word “longevity” does not exist as a legal category in European Union law. There is no definition, no register, no certification scheme, and no authority empowered to decide what may or may not describe itself as a longevity product, a longevity clinic, or a longevity company.